Observed Signal · Nov 12, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 1/5 · Sentiment: Positive
Biomatter Raises $18M for AI Enzyme Design
Biomatter, a Vilnius-based enzyme design company, has raised $18 million (€16.2 million) in an oversubscribed Series A round led by Astanor, with participation from existing investors UVC Partners, Inventure, and Metaplanet. Using an AI-driven platform, the company designs custom enzymes from first principles, reducing development time from months or years to weeks. Biomatter has delivered over 50 custom enzymes to more than 25 enterprise clients, including AstraZeneca, BASF, Sanofi, Thermo Fisher Scientific, and Kirin Holdings. Its enzymes are used in commercial products, such as for mRNA research, developed with Thermo Fisher Scientific. The new funding will support a 2,000-square-metre design-and-testing facility in Vilnius, scheduled to open in 2027, and expand commercial operations in the United States.
Funding for AI-driven enzyme design is relevant to biotech, not directly to AdTech/MarTech or advertising. No direct impact on the digital advertising ecosystem.
Track Sanofi Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Biomatter raised $18 million (€16.2 million) in an oversubscribed Series A round led by Astanor.
- Investors included UVC Partners, Inventure, and Metaplanet.
- Biomatter uses an AI-driven platform to design custom enzymes in weeks, not years.
- The company has delivered over 50 enzymes to more than 25 enterprise clients, including AstraZeneca, BASF, Sanofi, Thermo Fisher Scientific, and Kirin Holdings.
- A 2,000 m² facility in Vilnius will open in 2027, with US commercial expansion planned.
Connected Companies & Entities
“developed custom enzymes for enterprise customers across Europe, the United States and Japan, including AstraZeneca, BASF, Sanofi and Tereos...”
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
bit.bio Raises $25M Series D for Cell Models
bit.bio, a human cell programming company, announced it has closed a $25 million Series D funding round. The investment will be used to expand its portfolio of human cell models and increase access to its technology for pharmaceutical, biotechnology, and research organizations. The round includes participation from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam. The company's opti-ox™ platform enables the production of defined human cell types at scale, and its ioCells portfolio includes over 50 cell types for drug discovery and disease research. The funding comes as AI accelerates drug candidate identification and there is growing demand for alternatives to animal testing.
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
Receive all future signals for Sanofi & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.